PE20001333A1 - Proceso para estabilizar macrolidos de polieno - Google Patents

Proceso para estabilizar macrolidos de polieno

Info

Publication number
PE20001333A1
PE20001333A1 PE1999001209A PE00120999A PE20001333A1 PE 20001333 A1 PE20001333 A1 PE 20001333A1 PE 1999001209 A PE1999001209 A PE 1999001209A PE 00120999 A PE00120999 A PE 00120999A PE 20001333 A1 PE20001333 A1 PE 20001333A1
Authority
PE
Peru
Prior art keywords
stabilize
rapamycin
hydroxy
ethyl
refers
Prior art date
Application number
PE1999001209A
Other languages
English (en)
Inventor
Francois Navarro
Guy Stone
Samuel Petit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001333A1 publication Critical patent/PE20001333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO PARA ESTABILIZAR UN MACROLIDO DE POLIENO TAL COMO RAPAMICINA, 40-O-(2-HIDROXI)-ETIL-RAPAMICINA QUE COMPRENDE: AGREGAR UN ANTIOXIDANTE UTILIZANDOSE HASTA EL 1%, SIENDO 2,6-DIBUTILO TERCIARIO-4-METILFENOL AL MACROLIDO PURIFICADO. TAMBIEN SE REFIERE A UNA MEZCLA SOLIDA DE MACROLIDO DE POLIENO Y UN ANTIOXIDANTE Y A LA FORMA CRISTALINA DE 40-O-(2-HIDROXI)ETIL-RAPAMICINA QUE SE CARACTERIZA POR SU CELOSIA DE CRISTAL. TAMBIEN SE REFIERE A UN PROCESO PARA PURIFICAR 40-O-(2-HIDROXI)ETIL-RAPAMICINA
PE1999001209A 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno PE20001333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE20001333A1 true PE20001333A1 (es) 2000-12-12

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001209A PE20001333A1 (es) 1998-12-07 1999-12-03 Proceso para estabilizar macrolidos de polieno

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP2269651A3 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1876657B (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2732620C (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ302210B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU230174B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY120594A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL208854B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK286688B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI248938B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
CA2475383C (en) 2002-02-13 2009-12-22 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
CA2493878C (en) * 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE04758730T1 (de) * 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
DK1558622T3 (da) 2003-07-24 2008-02-25 Teva Gyogyszergyar Zartkoeruee Fremgangsmåde til oprensning af macrolider
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005056103A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
JP2008514706A (ja) * 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
EP2576590A1 (en) * 2010-06-07 2013-04-10 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US20190038605A1 (en) * 2015-09-18 2019-02-07 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
US20190290631A1 (en) 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
JP2023519875A (ja) * 2020-03-27 2023-05-15 ボストン サイエンティフィック サイムド，インコーポレイテッド 薬品の結晶化のための方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物

Also Published As

Publication number Publication date
ATE365051T1 (de) 2007-07-15
ITMI992520A1 (it) 2001-06-02
IL143092A0 (en) 2002-04-21
PT1137439E (pt) 2007-09-25
AU759219B2 (en) 2003-04-10
EP1743657A2 (en) 2007-01-17
EP1137439B1 (en) 2007-06-20
IT1319701B1 (it) 2003-10-27
KR20060096477A (ko) 2006-09-11
CA2351580C (en) 2012-03-20
AR026102A1 (es) 2003-01-29
US6605613B2 (en) 2003-08-12
TWI270550B (en) 2007-01-11
PL208854B1 (pl) 2011-06-30
DK1137439T4 (da) 2012-03-19
US20080161334A1 (en) 2008-07-03
US20020032213A1 (en) 2002-03-14
NO20121113L (no) 2001-05-16
DE69936352T2 (de) 2008-02-14
AU1657300A (en) 2000-06-26
WO2000033878A3 (en) 2000-11-02
AR054444A2 (es) 2007-06-27
CA2651609A1 (en) 2000-06-15
CA2732620C (en) 2013-08-06
US7297703B2 (en) 2007-11-20
FR2786771A1 (fr) 2000-06-09
EP1137439B2 (en) 2011-11-23
EP1137439A2 (en) 2001-10-04
CZ302210B6 (cs) 2010-12-22
US7572804B2 (en) 2009-08-11
RU2243769C2 (ru) 2005-01-10
SI1137439T2 (sl) 2012-05-31
DE69936352D1 (de) 2007-08-02
ID29250A (id) 2001-08-16
NO334612B1 (no) 2014-04-22
US20090270441A1 (en) 2009-10-29
KR100695834B1 (ko) 2007-03-19
CO4980847A1 (es) 2000-11-27
HUP0104489A3 (en) 2004-05-28
US20050107418A1 (en) 2005-05-19
WO2000033878A2 (en) 2000-06-15
CN1374872A (zh) 2002-10-16
NZ511936A (en) 2003-10-31
CN1261163C (zh) 2006-06-28
HK1038889B (zh) 2008-01-25
EP2279751A2 (en) 2011-02-02
NZ527781A (en) 2004-11-26
EP2269651A2 (en) 2011-01-05
TR200101416T2 (tr) 2002-01-21
EP2269651A3 (en) 2011-03-09
CN1876657B (zh) 2013-01-09
TWI248938B (en) 2006-02-11
CZ303006B6 (cs) 2012-02-22
ES2288033T5 (es) 2012-04-10
DE69936352T3 (de) 2012-05-03
MY120594A (en) 2005-11-30
GB9904934D0 (en) 1999-04-28
MY127579A (en) 2006-12-29
CZ20012001A3 (cs) 2001-09-12
NO20012424L (no) 2001-05-16
TR200201428T2 (tr) 2002-12-23
HU230174B1 (hu) 2015-09-28
JP5043308B2 (ja) 2012-10-10
US20030191148A1 (en) 2003-10-09
ZA200104360B (en) 2002-01-16
GB9826882D0 (en) 1999-01-27
NO20012424D0 (no) 2001-05-16
BR9915986A (pt) 2001-09-04
SK287325B6 (sk) 2010-07-07
FR2786771B1 (fr) 2002-12-27
HK1038889A1 (en) 2002-04-04
US6852729B2 (en) 2005-02-08
NO332698B1 (no) 2012-12-10
JP2006111637A (ja) 2006-04-27
EP2279751A3 (en) 2011-02-16
JP2002531527A (ja) 2002-09-24
SK7662001A3 (en) 2001-12-03
KR20010101128A (ko) 2001-11-14
US7741338B2 (en) 2010-06-22
JP3805625B2 (ja) 2006-08-02
SG151072A1 (en) 2009-06-29
BE1012869A3 (fr) 2001-04-03
HUP0104489A2 (hu) 2002-03-28
ES2288033T3 (es) 2007-12-16
PL348333A1 (en) 2002-05-20
EP1743657A3 (en) 2007-03-28
SI1137439T1 (sl) 2008-06-30
JP2005200429A (ja) 2005-07-28
SK286688B6 (sk) 2009-03-05
PL196627B1 (pl) 2008-01-31
CA2351580A1 (en) 2000-06-15
JP5165199B2 (ja) 2013-03-21
CA2732620A1 (en) 2000-06-15
HU228939B1 (en) 2013-07-29
TW200540179A (en) 2005-12-16
CN1876657A (zh) 2006-12-13
ITMI992520A0 (it) 1999-12-02
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
AR048073A2 (es) 2006-03-29

Similar Documents

Publication Publication Date Title
PE20001333A1 (es) Proceso para estabilizar macrolidos de polieno
PT915898E (pt) Forma i cristalina de claritromicina
PE20090696A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
CY1113383T1 (el) Μεθοδος για την παρασκευη (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
PE20050355A1 (es) Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
BRPI0410705A (pt) forma cristalina de agonista de receptor 2 adrenérgico
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR023071A1 (es) Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
CR9540A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
DOP2006000289A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
BRPI0413848B8 (pt) composto, processo para preparar o composto, composição terapêutica para prevenir inflamação e apoptose, processo para preparar a composição terapêutica e uso de composto, ou de seu sal, ou de seu estereoisômero
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
UY26256A1 (es) Amidas de ácidos carboxílicos, medicamentos que contienen estos compuestos, su utilización y su preparación
BR9713261A (pt) Tricìclicos substituìdos
EA200200819A1 (ru) Кристаллическая форма ii линезолида
AR057291A1 (es) Proceso para la preparacion de acidos bisfosfonicos geminales y las sales y/o hidratos farmaceuticamente aceptables de los mismos, una composicion farmaceutica que los contiene y el uso de esta en el tratamiento de la osteoporosis
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
ECSP034598A (es) Compuesto lactamico

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term